Madhav Thambisetty

National Institutes of Health — United States

Medicine · Health Sciences

60h-index14.0kcitations218works18.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(98), Dementia and Cognitive Impairment Research(61), Metabolomics and Mass Spectrometry Studies(33), Bioinformatics and Genomic Networks(23), Computational Drug Discovery Methods(17)

Publications217 total

Longitudinal associations between medication use and phenotypic aging: insights from the Baltimore longitudinal study of aging
The Journals of Gerontology Series A·2025Open Access
Longitudinal progression of blood biomarkers reveals a key role of reactive astrocytosis in preclinical Alzheimer’s disease
Med·2025· 7 cited
Amyloid-related iatrogenic atrophy of the brain: data transparency is an urgent safety priority
The Lancet Neurology·2025· 4 cited
Population‐Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study
Clinical Pharmacology & Therapeutics·2025· 4 citedOpen Access
Communicating scientific evidence: drugs for Alzheimer’s disease as a case study
Current Medical Research and Opinion·2025· 3 cited
Loneliness and Biomarkers of Alzheimer’s Disease, Axonal Damage, and Astrogliosis: A Coordinated Analysis of Two Longitudinal Cohorts
The Journals of Gerontology Series B·2025· 3 citedOpen Access
Temporal order of gait speed decline relative to changes in measures affected early in Alzheimer’s disease
Alzheimer s & Dementia·2024Open Access
Proteome‐wide analyses identifies plasma immune regulators of amyloid‐beta progression
Alzheimer s & Dementia·2024Open Access
Comparison of amyloid positron emission tomography, hippocampal volume, and plasma biomarkers in predicting conversion to mild cognitive impairment
Alzheimer s & Dementia·2024Open Access
Comparison of amyloid positron emission tomography, hippocampal volume, and plasma biomarkers in predicting conversion to mild cognitive impairment
Alzheimer s & Dementia·2024· 1 citedOpen Access
Sex differences in the trajectories of plasma biomarkers, brain atrophy, and cognitive decline relative to amyloid onset
Alzheimer s & Dementia·2024· 12 citedOpen Access
Drug Repurposing for Effective Alzheimer’s Disease Medicines: Existing Methods and Novel Pharmacoepidemiological Approaches
Advances in Alzheimer's disease·2024
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation
UNC Libraries·2024Open Access
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation
JAMA Neurology·2024· 270 citedOpen Access
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience
Molecular Neurodegeneration·2024· 13 citedOpen Access
Drug Repurposing for Effective Alzheimer’s Disease Medicines: Existing Methods and Novel Pharmacoepidemiological Approaches
Journal of Alzheimer s Disease·2024· 2 cited
Challenges in a Biological Definition of Alzheimer Disease
Neurology·2024· 20 citedOpen Access
Sex differences in the trajectories of plasma biomarkers, brain atrophy, and cognitive decline relative to amyloid onset
2024· 1 citedOpen Access
Proteome-wide analysis identifies plasma immune regulators of amyloid-beta progression
Brain Behavior and Immunity·2024· 11 citedOpen Access
Psychosocial experiences are associated with human brain mitochondrial biology
Proceedings of the National Academy of Sciences·2024· 35 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Juan C. Troncoso(18), Susan M. Resnick(18), Yang An(17), Cristina Legido‐Quigley(12), Simon Lovestone(12), Allan I. Levey(10), Richard O’Brien(10), James J. Lah(9), Nicholas T. Seyfried(9), Abdul Hye(9), Eric B. Dammer(8), Duc M. Duong(8), Sudhir Varma(8), Olga Pletniková(8), Luigi Ferrucci(8), Thomas S. Wingo(6), Kaj Blennow(6), Vijay R. Varma(6), Dean F. Wong(6), David A. Bennett(5)